A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure on Standard Heart Failure Therapy
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Recombinant human neuregulin 1-beta (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Sponsors Zensun (Shanghai) Sci & Tech
- 25 Jul 2024 Status changed from active, no longer recruiting to completed.
- 13 Jan 2022 Planned number of patients changed from 1000 to 140.
- 13 Jan 2022 Planned End Date changed from 31 Dec 2021 to 20 May 2022.